Papillary neoplasms of the breast: a review.
The common feature characterizing papillary lesions is a papillary, arborescent epithelial proliferation supported by fibrovascular stalks with or without an intervening myoepithelial (ME) cell layer. Papillary lesions of the breast include intraductal papilloma, papillomatosis, atypical papilloma (or papillomatosis), carcinoma arising in a papilloma, and intraductal papillary carcinoma (with or without invasion). Distinction of these subtypes is not always an easy task. Adding to the difficulties, there are, currently, different terminologies and criteria used to categorize the variety of papillary lesions; some of these are not necessarily outcome based. When a papillary lesion is encountered in the breast, the most important question to answer is whether it is benign or malignant. The complete absence of an ME cell layer in the fibrovascular fronds of a papillary lesion indicates a carcinoma; however, the presence of ME cells does not invariably exclude the diagnosis of intraductal papillary carcinoma. (1) Therefore, the role of ME markers and immunohistochemistry in the assessment of papillary lesions will be addressed. It is important to note that the significance of the complete absence of an ME cell layer for papillary lesions composed purely of uniform apocrine cells is not well established.
Furthermore, depending on their location in the mammary duct system, papillary lesions may be solitary, centrally (subareolar) located or multifocal, and peripherally located within terminal duct-lobular units. These are associated with different risks for associated carcinoma or subsequent carcinoma. Whether the lesion is located simply in the distal portions of the duct system, but not necessarily in the terminal duct-lobular unit, is not always clear cut. Therefore, the designations of papillomatosis and multifocal intraductal papillary carcinoma are often arbitrarily applied for multiple microscopic lesions generally separated by uninvolved mammary tissue; the terms papilloma and papillary intraductal carcinoma have been used for the centrally located lesions. Three dimensional studies, however, can reliably determine the precise location within the duct system and accurately distinguish the two categories. (2)
This review will address the morphologic spectrum and the diagnostic problems associated with papillary lesions as well as incorporating the concept of ductal intraepithelial neoplasia (DIN) into the terminology.
Precise classification of papillary lesions of the breast on fine-needle aspiration remains a challenging area in cytology. (3) Of particular significance is the difficulty in distinguishing between benign and malignant papillary lesions on the basis of cytology, although a few authors have reported some useful discriminating features to aid in the differential diagnosis between the two. (4-6) Most studies, however, report low concordance between cytologic and histologic diagnoses of papillary lesions. (7-9)
Papillomas usually yield highly cellular smears containing clusters of ductal cells, often with a papillary configuration, and readily identifiable bipolar cells that represent ME cells. (4) Sheets of apocrine cells and a proteinaceous background with histiocytes and siderophages may also be present. The cytology of fibrocystic changes, radial scars, fibroadenoma, low-grade ductal carcinoma, or apocrine carcinoma often appear similar, however, to that of papillary lesions. (10,11)
With the excellent samples obtained by needle-core biopsies, there is no need, in our opinion, to perform aspiration biopsies. Furthermore, if imaging studies were able to clearly identify a papillary lesion in women of all ages, including those 45 years or younger, when the likelihood of carcinomas is less, complete excision of the lesion with a rim of uninvolved breast tissue would be the optimal approach. Any needling procedure by either aspiration or core biopsy can introduce artifacts with significant impact on the ultimate diagnosis.
PAPILLARY LESIONS DIAGNOSED ON CORE BIOPSY
Whether or not all papillary lesions identified on core biopsies should be surgically excised remains a controversial issue. In all cases in which a papillary lesion is identified on a core biopsy, correlation with clinical, mammographic, and sonographic findings is crucial. Some investigators (12-16) have suggested that papillary lesions can be diagnosed accurately on core needle biopsies and that papillomas without atypia can be followed up without surgical excision. Based on available data, we cannot endorse leaving behind a papillary lesion based on evaluation of a small portion of the lesion by a core biopsy. Rizzo et al (17) advocated surgical excision of all intraductal papillomas identified on core needle biopsies because of an upgrade of almost a fourth of these lesions caused by the presence of either atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS) on subsequent surgical excision. Another study (18) also found a malignancy in the subsequent excisional biopsy in a quarter of patients with papillary lesions classified as probably benign on a core biopsy. Valdes et al (19) similarly found that 23% of papillary lesions without atypia on fine-needle aspiration biopsy, core needle biopsy, or mammotome were malignant at surgical excision. The authors (17) concluded that no distinctive clinical, radiologic, or cytologic signs could distinguish between a papilloma and a papillary carcinoma; they recommended, therefore, surgical excision of all papillary lesions diagnosed on percutaneous needle biopsies.
Clearly, with 3 to 4 cores (obtained with a 14-gauge needle) of a 2.5-cm papillary lesion showing completely benign features, it is impossible to predict what may be present in the residual lesion; complete excision should be performed on such a case. On the other hand, a 0.5- to 1-cm lesion, sampled with 3 to 4 cores by an 8- to 9-gauge needle, which shows a benign lesion, was probably excised nearly in its entirety given the 4- to 6-mm width of cores obtained by 8- to 9-gauge needles. When atypia is present in a papillary lesion on core biopsy, a designation of "an at-least atypical papillary lesion" would be appropriate until a definite classification can be made based on the subsequent excisional biopsy. Because of potential histologic variability within a papillary lesion, complete excision is prudent in most cases, regardless of the findings on an initial core biopsy that has not removed the lesion in its entirety.
Intraductal papillomas are generally solitary and located in the subareolar region in the major and lactiferous ducts, hence the derivation of the term central/solitary papilloma. They occur most frequently in women older than 50 years and are often present with serous or serosanguinous nipple discharge. (20-22) A circumscribed mass or a solitary dilated retroareolar duct may be seen on mammography or ultrasonography in the case of larger lesions; smaller lesions are usually occult. (21,23-25) Calcifications are rarely detected in papillomas but do occur in both large and small papillary lesions. (21,23,24) Galactography may demonstrate a smooth filling defect or a complete obstruction to retrograde flow of contrast material. (21) Magnetic resonance imaging may show a well-defined enhancing lesion within a fluid-filled duct. (26)
Papillomas are characterized by an arborescent proliferation with epithelial and ME cells overlying fibrovascular stalks protruding into ductal lumens. Epithelial cells line the luminal aspect of the papillae, and an ME cell layer is present between the epithelial cells and the basement membrane (Figure 1, A through D).
Epithelial proliferations of the low-risk DIN (intraductal hyperplasia) type without cytologic atypia are frequently observed either focally or diffusely in papillomas. When prominent and forming solid sheets, the proliferating epithelial cells often obscure the papillary nature of the lesion. At higher magnification, however, delicate fibrovascular cores with intervening ME cells are often apparent (Figure 2, A through C). In some planes of the section, the fibrovascular stalk may not be apparent at all, resulting in an interpretation of pure low-risk DIN (intraductal hyperplasia). These areas of diffuse or florid hyperplasia show streaming or whorling of the proliferating cells; have irregularly distributed and often overlapping, bland nuclei; and have inconspicuous cytoplasmic margins and slitlike secondary lumens; all these features are clues indicating a benign process.
When there is sclerosis in the papillary processes, the lesion qualifies as a sclerosing papilloma; the amount of sclerosis is highly variable, ranging from focal to diffuse. Distorted tubules entrapped in the sclerotic areas may create a pseudoinvasive pattern (Figures 3, A through D, and 4, A and B); the identification of persistent ME cells around these entrapped ducts confirms their benign nature.
Aside from apocrine metaplasia, which is rather common in papillomas, squamous, mucinous, clear cell, and sebaceous metaplasia may also occur at much lower frequency. As a rule, microcalcifications are not a common feature of either solitary/central or peripheral/multifocal papillary lesions, whether benign or malignant. When microcalcification is encountered, it is most frequently in the setting of a sclerosing papilloma.
Hemorrhagic infarction because of torsion of the papillary stalk may hinder accurate interpretation of the lesion. In cases of extensive infarction, diagnoses should be based on any remaining viable tissue; if there is no viable tissue remaining, then the lesion is designated as an infarcted papillary lesion.
[FIGURE 1 OMITTED]
Classic papillomatosis, also referred to as peripheral/multiple papillomas, is characterized by papillary proliferations within multiple terminal duct-lobular units or in the distal branches (terminal ducts) of the duct system. Patients with papillomatosis are generally younger than those with either solitary/central papilloma or papillary carcinoma. (27) Papillomatosis may occasionally present with nipple discharge or a mass lesion when extensive; however, it is most often an incidental microscopic finding. When present in abundance, nodular masses or, rarely, microcalcifications may be seen on mammography.
The morphologic appearance is similar to intraductal papillomas. However, although the attachment to the duct wall is seen only focally or, at most, in a few foci in solitary papillomas, it is more common to find simultaneous protrusion and proliferation of several papillae with multiple points of attachment in papillomatosis.
ATYPICAL PAPILLOMA AND CARCINOMA ARISING IN A PAPILLOMA
Papillomas can display focal proliferations of a mildly atypical, monotonous cell population identical to low grade DIN (DIN 1/ADH/DCIS, grade 1; Figures 5, A through F, and 6, A through C). When DIN 1 occupies less than a third of the papillary lesion, the term atypical papilloma has been used. If at least a third, but less than 90% of the lesion displays such changes, the designation of carcinoma arising in a papilloma has been used. When completely excised, these 2 groups do not seem to differ in clinical behavior, as observed in a retrospective study (28) that used this quantitative approach. It is noteworthy that although 90% was used as the cut-off point, none of the lesions had atypical areas that occupied more than 65% to 70% of the papillary lesion. Currently, to avoid the term carcinoma, we designate all such lesions as papillomas with DIN 1/atypical papilloma (Table 1). Rarely, papillomas may display focal areas similar to grade 2 or grade 3 DIN (DCIS, grades 2-3). Again, our preference is to designate these lesions as papillomas with focal DIN 2 to DIN 3/ DCIS, grade 2 to grade 3, or DIN 2 to DIN 3/DCIS, grade 2 to grade 3 arising in a papilloma. The main reason we prefer to designate these as DINs and specify the grade and extent is that even a fully developed intraductal or intracystic papillary carcinoma is known to have an excellent prognosis with nearly 100% survival at 10 years. (29)
[FIGURE 2 OMITTED]
Variable criteria have been used for diagnosing an atypical papilloma. (30,31) Page and colleagues (30) categorize a lesion as a papilloma with DCIS, when the papilloma shows any area of uniform histology and cytology consistent with noncomedo DCIS that is greater than 3 mm in size, whereas papillomas that contain a histologically identical epithelial proliferation that is greater or equal to 3 mm in size are classified as papillomas with atypia. (30) Although outcome data of atypical papillomas diagnosed based on the Page et al (30) criteria have been reported, the number of cases, to our knowledge, has been limited; there were 8 patients with atypical hyperplasia within the papillomas and there were no papillomas with DCIS in the study. (30) Others, such as Collins et al, (32) do not rely on the extent/ size of the atypical proliferation and render a diagnosis of atypical papilloma when the atypical proliferation in the papilloma demonstrates some, but not all, of the combined architectural and cytologic features that have been proposed for low-grade DCIS. These criteria have been adopted or analogized from conventional criteria for differentiating ADH and DCIS in mammary ducts without papilloma. Given the significant interobserver variability in the application of these criteria in the setting of pure epithelial proliferation, its superimposition on papillary lesions is unlikely to have much utility.
The possible outcome of applying only qualitative criteria or nonproportional quantitative criteria would be that many localized larger papillomas with only a small proportion of low-grade, atypical proliferation would be categorized as carcinomas. Such lesions require only localized excision with a complete rim of uninvolved breast tissue and have an excellent prognosis; (28) designating them as carcinoma might prompt unwarranted treatment and cause undue alarm simply for finding a 3-mm focus of low-grade DIN (DCIS, grade 1) in a 3-cm, otherwise benign papilloma.
IMMUNOHISTOCHEMICAL FEATURES OF PAPILLARY LESIONS
The distinction of benign and malignant papillary lesions based on hematoxylin-eosin (H&E) morphology can be very challenging, especially in cases where there is limited and/or fragmented material, as in core biopsies. In recent years, there has been a considerable increase in the number of different antibodies available for use in the diagnosis of breast lesions. A summary of immunohistochemical features for the differential diagnosis of papillary lesions is provided in Table 2.
In our experience, high molecular weight cytokeratins, ME cell markers, and basement membrane markers are most helpful in distinguishing papillary lesions suspicious for having atypia, carcinoma, or invasion. The absence of an ME cell layer throughout an intraductal papillary lesion generally confirms a diagnosis of papillary DIN (papillary DCIS). The significance of the total absence of ME cells in apocrine papillary lesions lacking atypia is not well established and requires further evaluation. The identification of ME cells by markers, such as p63, calponin, and CD10 is very helpful in supporting a diagnosis of papilloma when processing artifacts blur the morphologic differences between the epithelial and ME cell layers on H&E section.
[FIGURE 3 OMITTED]
[FIGURE 4 OMITTED]
[FIGURE 5 OMITTED]
[FIGURE 6 OMITTED]
High molecular weight cytokeratins (CK) are typically found in ductal epithelial lining and squamous epithelium. The antibody 34pE12 identifies a cocktail of acidic and basic CK, including CK1, CK5, CK10, and CK14. (33-35) In the normal breast, CK5/6 and 34[beta]E12 stain the ME cells and mammary duct epithelial cells. Several studies have demonstrated the diminished to absent immunoreactivity to CK5/6 and 34[beta]E12 in 80% to 100% of low-grade to high-grade DIN (ADH/DCIS) lesions, whereas 88% to 100% of benign intraductal proliferations (low-risk DIN/intraductal hyperplasia) display strong mosaic distribution of immunoreactivity throughout the lesions. (36-40) The atypical neoplastic cell population within a papilloma with DIN (an atypical papilloma and carcinoma arising in a papilloma) is also frequently negative for CK5/6 and 34[beta]E12 (Figure 4). A combination of ME cell markers and antibodies to high molecular weight cytokeratins, such as CK5/6 and 34[beta]E12, may be more useful in the differentiation of papillomas and papillary carcinomas. (41-43) Cytokeratin 34[beta]E12 has the advantage of simultaneous decoration of the ME cells while identifying the proliferating cells as low-risk DIN or DIN 1 to DIN 3.
CLINICAL SIGNIFICANCE OF PAPILLOMAS AND PAPILLOMATOSIS WITH OR WITHOUT ATYPIA
In the distant past, papillomas were regarded as malignancies or as precancerous lesions and were treated by simple or radical mastectomy. (44,45) Studies demonstrating the benign nature of papillomas led to acceptance of local excision as the treatment of choice. (3,22,46-48) Subsequently, however, an increased risk for breast cancer was reported in patients with papillomas, (49,50) and a higher incidence rate was noted in association with multiple papillomas. (22,48,51) The risk of developing cancer after a biopsy with papillomatous lesions was reported to be 7.4 times that of the normal population of comparable age. (51) However, the influence of atypia was not a feature evaluated in these early studies. Furthermore, the risk of subsequent cancer is also affected by the presence of other coexisting proliferative lesions, which are frequently evident in the proximity of many papillary lesions (22,51); the extent of surgical excision (complete versus incomplete, ie, with or without a rim of uninvolved mammary tissue) is another feature not assessed and/or noted in many earlier studies. It is important to note that these earlier studies did not have the extensive tissue sampling employed today. A thorough review of the "Materials and Methods" sections of the older studies confirms the limited or absent information available on the number of slides per lesion and/or specimen size.
Compared with solitary papillomas, papillomatosis is more likely to be associated with atypia or DIN. In a retrospective study of multiple papillomas, (52) most patients with multiple papillomas (44 of 61; 72%) had coexisting atypical or malignant epithelial lesions. In another study of 25 papillary lesions, (53) 6 of 16 patients (38%) with peripheral papillomas had associated carcinomas compared with none of 9 patients (0%) with central papillomas.
With the growing awareness of the presence of atypical proliferations in papillary lesions, a few studies attempted to determine the impact of such finding on the relative risk of subsequent breast cancer. (30,54) Page et al (30) reported the risk of subsequent invasive breast carcinoma for papillomas containing atypical hyperplasia to be greater than 4 times that of patients with papillomas lacking atypical hyperplasia, whereas the risk for papillomas lacking atypical hyperplasia closely approximated the risk of proliferative disease without atypia.
In a retrospective study of 119 central papillomas, MacCrogan et al (28) found no statistical difference in recurrence among several categories of papilloma with epithelial proliferation: papillomas with florid hyperplasia (22 patients; 18%), papillomas with focal atypia (40 patients; 34%), atypical papillomas (24 patients; 20%), and carcinomas arising in a papilloma (33 patients; 28%). The uneventful outcomes for these patients could be explained by the complete excision of the atypical cell population localized to a lesion confined to a dilated segment of a duct. Recurrences appeared to be related to the presence of proliferative lesions in the surrounding breast tissue. (28)
A more recent, larger study (31) addresses the impact of multiplicity as well as atypia on subsequent breast cancer risk. The study (31) included 372 solitary papillomas, of which 54 had atypical hyperplasia (15%), and it included 41 multiple papillomas, of which 13 had atypical hyperplasia (32%). The atypical hyperplasia (ADH and/or atypical lobular hyperplasia) was identified either within the papilloma or in the nearby terminal duct-lobular units (ADH was defined as an architecturally complex, cribriform-like proliferation of monotonous cells that lacked malignant cytologic features and was confined to an area measuring <3 mm at the greatest dimension and only partially involving a "basement membrane-bound space," with a second nonatypical population of cells composing the remainder of the papilloma). After a mean follow-up of 16 years, patients with a single papilloma lacking atypia had a 2-fold risk of developing breast cancer, similar to the relative risk of 1.9 for patients with proliferative disease without atypia. The relative risk associated with single papillomas with atypia was elevated (relative risk, 5.1) and was even slightly higher than the relative risk of 4.1 associated with nonpapillary ADH. Patients with multiple papillomas had a higher relative risk (3.0) than patients with single papillomas or proliferative disease without atypia; multiple papillomas with atypia had an even higher relative risk (7.0). This study evaluated cases collected at Mayo Clinic (Rochester, Minnesota), between 1967 and 1991, and there is no mention of lesion size or sampling method; furthermore, the inclusion of cases that had simultaneous nonpapillary proliferative lesions detracts from the validity of extrapolating the risk to pure papillary lesions.
INTRAEPITHELIAL NEOPLASIA CONCEPT AND PAPILLARY LESIONS
Our current preference is to use the term ductal intraepithelial neoplasia (1, 2, or 3, as the case may be) for pure epithelial lesions rather than atypical intraductal hyperplasia or DCIS. We prefer to use these latter terms in the setting of papillary lesions as well to avoid the designation of carcinoma. A papillary DCIS would become DIN 1 (or rarely, DIN 2 or DIN 3), papillary type. Atypical papilloma would be designated as papilloma with DIN 1; the proportion of the lesion involved by the DIN 1 should be specified. In rare cases when a higher-grade DIN (DCIS, grades 2 or 3) focally involves a papilloma, it would be designated as a papilloma with DIN 2 or DIN 3.
INTRADUCTAL PAPILLARY CARCINOMA (DIN 1-3, PAPILLARY TYPE)
Definition and Clinical Presentation
Intraductal papillary carcinomas account for 2% of all breast cancers. (47) Most occur during the fifth and sixth decades of life. It is important to distinguish solitary, central papillary carcinomas from the multifocal, peripheral type, as the latter may require a wider excision because of the more extensive distribution of the process. Multifocal peripheral intraductal papillary carcinoma is basically a variant of the classic DIN 1 to DIN 3 (intraductal carcinoma) because it originates in the terminal duct-lobular unit and is distributed in the same manner and, therefore, requires similar management.
The complete or nearly complete (90%) absence of ME cells within the intraluminal papillary fronds is one of the most important distinguishing features of papillary intraductal carcinoma. The presence of ME cells, even extensively, does not necessarily exclude the possibility of a papillary intraductal carcinoma, however. (1,43,55) Furthermore, even in the setting where there is a near absence of ME cells in the papillary processes, the ME cell may be present in the surrounding duct wall. The epithelial cells supported by the fibrovascular stalks can display a variety of proliferative patterns, including cribriform, solid, micropapillary, or stratified spindle-cell patterns (Figure 7, A through D). The neoplastic cells often appear deceptively bland and are categorized as low grade. High-grade intraductal papillary carcinomas do occur, albeit with lower frequency. Features useful for differentiating intraductal papillomas, atypical papillomas, and papillary intraductal carcinomas are summarized in Table 1. Localized apocrine metaplasia is generally not a feature of papillary intraductal carcinomas, although rarely, complete apocrine differentiation may be present, called apocrine papillary intraductal carcinoma. These apocrine papillary carcinomas often display abundant epithelial proliferation in solid or cribriform pattern, often with at least focal atypia overlying the fibrovascular stalks. Whether or not an apocrine lesion with an absent ME cell layer but only one layer or minimally stratified epithelial cell layer qualifies as DIN 1, papillary type (papillary DCIS, grade 1) has not been well established.
Immunostain for ME markers (calponin, p63, CD10, etc) are useful in unmasking the presence and extent of distribution of ME cells in papillary lesions and can be helpful in arriving at an accurate diagnosis. One of the problematic areas in interpretation of these lesions is how to manage a lesion in which there is complete absence of an ME cell layer, even around the cystically distended duct in which the papillary lesion is proliferating. Does the absence of an ME cell layer around a duct constitute or reflect invasion? This problem is often compounded when needle instrumentation results in partial spillage of the duct content into the surrounding stroma. This issue is discussed below.
Variants of Intraductal Papillary Carcinoma.--Intracystic (Encapsulated) Papillary Carcinoma.--Intraductal papillary carcinomas that are solitary, and frequently, centrally located, have also been designated intracystic (encysted) papillary carcinomas by some authors. (29,56,57) The term intracystic may be appropriate for lesions that grossly exhibit a cystic space around the papillary proliferation; however, it serves no distinctive purpose because, morphologically, all intraductal papillary carcinomas are located within a variably dilated cystic duct.
The term encapsulated papillary carcinoma has been coined for papillary carcinomas that appear circumscribed and encapsulated but which lack demonstrable ME cells around the cystically dilated duct. (58,59) The possibility that a subset of circumscribed papillary carcinomas lacking a demonstrable peripheral ME cell layer may actually represent invasive papillary carcinomas has been raised by some authors. (59,60) In our opinion, however, these tumors are well delineated and behave indolently and are best regarded as intraductal papillary carcinomas for management purposes, particularly if persistence of a basement membrane around the duct can be ascertained with collagen IV or laminin immunostains.
Microglandular adenosis is a notable example of a benign lesion with complete absence of an ME cell layer; in this setting, the basement membrane is actually multilayered and thickened, possibly to compensate for the loss of the ME cell layer. Nevertheless, although the absence of detectable ME cells in a duct wall may not necessarily indicate stromal invasion, this finding should prompt a careful evaluation for possible invasion. In case of larger lesions ([greater than or equal to] 3 cm), it would be prudent to assess sentinel nodes, just as many prefer to assess sentinel nodes for extensive DIN 1 to DIN 3 (DCIS, grades 1-3).
Nassar et al (61) described 19 circumscribed solid papillary carcinomas that appeared noninvasive on H&E morphology alone. No immunohistochemical stains were performed to assess the ME cell layer. No metastatic disease was found in the lymph node dissections performed for 12 of the patients (63%). The 12 patients were alive with no evidence of disease at a mean follow-up of 5.7 years, and 6 were dead (32%) of unrelated causes at a mean of 11.5 years, indicating that most papillary carcinomas that appear to be in situ by H&E morphology are clinically indolent and behave like noninvasive carcinomas.
Rare cases of similar tumors with axillary lymph node metastasis have been reported in the literature. (29,62,63) The ultimate outcome, even with nodal metastasis, has been reported as favorable, with 100% disease-specific survival rate within 10 years of follow-up. (29,63) It is possible that these cases may have had occult foci of invasion undetected by the sampling, that a separate occult primary tumor had existed, or that the lymph node tumor could actually have represented a carcinoma arising from a glandular inclusion (although this would be, admittedly, quite rare). Another possibility is that many of these lesions receive a needle core or aspiration biopsy before excision. Most of these lesions are also located in the nipple/subareolar region, where a rich lymphatic network exists. It is conceivable that manipulation and instrumentation of these often large and friable lesions may dislodge tumor cell fragments into the lymphatic channels from where they can be easily transported to the axillary nodes; the nodal involvement may reflect benign transport in, at least, some cases.
[FIGURE 7 OMITTED]
Solid Papillary Carcinoma.--The term solid papillary carcinoma (SPC) was first proposed by Maluf and Koerner (64) to describe a variant of intraductal papillary carcinoma, which is characterized by a compact cellular proliferation within multiple nodules that represent dilated ducts (Figure 8, A through C). The neoplastic tumor cells are low to intermediate grade and appear to be streaming, so that the lesion resembles florid intraductal hyperplasia at low magnification. However, the homogeneity (monotony) of the neoplastic cells, as well as the presence of significant mitotic activity in some cases, are clues to the diagnosis of SPC. Many of these cases display neuroendocrine differentiation, often have at least focal granular eosinophilic cytoplasm, and are immunoreactive with neuroendocrine markers. (64) Solid papillary carcinoma is thought to be one possible precursor of colloid (mucinous) carcinoma of the breast because of its frequent association with the latter, but other types of invasive carcinoma can also be seen in association with SPCs. (61,64)
Like intracystic (encapsulated) papillary carcinomas, the possibility that many of these SPCs actually represent "pushing-border" or "expansile" variants of invasive carcinoma has been raised by some authors (60,61,65); however, the behavior of these tumors is also generally indolent, (61,64) and even for SPCs with associated invasive carcinomas, the prognosis is relatively favorable compared with invasive ductal carcinomas of comparable size. In the series reported by Nassar et al, (61) only 17.8% (5 of 28) of patients who had SPC with invasive carcinoma died of the disease after a mean of 6.6 years (1-19 years). The size of the invasive component in the 28 cases varied from 0.1 cm to 4 cm; the invasive component was less than 0.5 cm in 9 cases (26.6%), 0.5 cm to 1 cm in 3 cases (8.8%), 1 cm to 2 cm in 12 cases (35.2%), and greater than 2 cm in 3 cases (8.8%); the size could not be determined in 7 cases (20.6%); the invasion was multifocal in 13 cases (38%). Axillary lymph node metastases were present in 6 cases (20%), and the invasive tumors in all 6 cases were less than 1.5 cm. Among the 5 patients who died of the disease (17.8%), the size of the invasive component measured less than 0.5 cm in 3 cases (60%) and 1 cm to 2 cm in 2 cases (40%); 1 patient (20%) had positive axillary nodes, and all 5 patients (199%) developed distant metastases. Although this could suggest that some small but aggressive clones do exist, it should be kept in mind that, even when an entire sample is submitted for pathologic evaluation, only a single slide of each block is evaluated: Our sampling is not exhaustive and could easily miss areas of invasive carcinoma hidden deeper in the blocks.
[FIGURE 8 OMITTED]
Invasive Carcinoma Associated With Papillary Carcinoma
Most papillary carcinomas are noninvasive; however, a small proportion of papillary carcinomas have unequivocal associated stromal invasion. The invasive foci generally display the morphology of an infiltrating duct carcinoma lacking papillary features (Figure 9, A and B). Morphologic variants include tubular carcinoma and infiltrating duct carcinoma not otherwise specified (NOS). The size of the invasive focus may range from microinvasive to substantial and grossly visible. (61,66)
Some authors reserve the term invasive papillary carcinoma to invasive carcinomas with an exclusively papillary pattern; these have been reported to account for less than 2% of all breast carcinomas (66-68) with a higher frequency of occurrence in postmenopausal and nonwhite women. (66) It is reasonable to speculate, however, that many invasive papillary carcinomas described in older studies may have included intraductal papillary carcinomas that appeared invasive in an expansile fashion, intraductal papillary carcinomas with associated invasive ductal carcinoma, and possibly even invasive micropapillary carcinomas. (66)
Epithelial Displacement After Needle Instrumentation Procedures
Epithelium displaced by a needle core or aspiration biopsy has been described in intraductal papillomas as well as in intraepithelial (in situ) and invasive neoplasms. The epithelium can be dislodged and displaced into the surrounding stroma, often in the needle tract, and even into adjacent lymphatic channels. (69) Displaced epithelium can even be transported to axillary lymph nodes. (69,70) It is important to be aware of the possibility of displacement after needle aspiration or core biopsy to distinguish displaced epithelium from true stromal or lymphovascular invasion.
Papillary lesions, because of their inherent friability, are particularly prone to epithelial displacement after needle instrumentation procedures. (71) The diagnosis of microinvasive or early invasive carcinoma associated with intraductal papillary carcinomas is frequently challenging, and the presence of displaced epithelium can cause much confusion in this setting. The history of a recent needling procedure, presence of prior biopsy site changes, degenerative changes in the "invasive" cell clusters, and absence of reactive, altered stroma surrounding the fragments of epithelium are clues indicating epithelial displacement (Figure 10, A and B).
[FIGURE 9 OMITTED]
[FIGURE 10 OMITTED]
INVASIVE MICROPAPILLARY CARCINOMA
Definition and Clinical Features
The term invasive micropapillary carcinoma (IMPC) of the breast was coined in 1993 to describe a distinct variant of breast cancer characterized by small micropapillary clusters of tumor cells that lack true, central, fibrovascular cores and that lie within empty stromal lacunae (72) (Figure 11, A through C). It is possible that the empty lacunae are, at some point, filled with fluid that is washed out by processing. Invasive micropapillary carcinoma is now a recognized subtype of infiltrating duct carcinoma. (73) It can occur in pure form or, more often, as a partial component admixed with infiltrating duct carcinoma NOS. Rare association with variants, including tubular, mucinous, or papillary carcinoma, and even infiltrating lobular carcinoma, has also been reported. (74-78) The incidence of IMPC is 0.9% to 1.7% of invasive breast carcinomas when occurring in pure form (79,80) and up to 7.6% when admixed with other types of mammary carcinoma. (74) The mean age at presentation is similar to that of patients with infiltrating duct carcinoma NOS. (72,74-77,80) Most of these patients present with a palpable mass; an abnormal density or micro-calcifications may also be detected on mammography. (72,76,78,81)
Most IMPCs are moderately or poorly differentiated with an intermediate to high nuclear grade. Expression of MUC1 in the stroma-facing surface (reversed apical pattern) of the tumor cells in IMPC has been demonstrated, consistent with its distinctive inside-out pattern. (76,82,83) An associated intraductal carcinoma of micropapillary, cribriform, or papillary type is frequently present, (72,74-78,80,81,84,85) which is a helpful clue when excluding the rare possibility of metastatic ovarian/peritoneal serous papillary carcinoma or metastatic micropapillary carcinoma from other organs, such as the lung or urinary bladder. On occasion, true lymphovascular invasion may be difficult to distinguish from the stromal spaces seen in the micropapillary pattern, and vascular markers, such as CD31, CD34, factor VIII, or D2-40, may be helpful.
[FIGURE 11 OMITTED]
The propensity of IMPC, whether in pure or mixed form, for lymphovascular invasion and lymph node metastasis is well known and documented in several reports. (72,74-78,80,81,84,85) Studies that categorized the tumors into groups according to the percentage of micropapillary component have found no correlation between the proportion of micropapillary carcinoma and the percentage of lymph node metastasis or lymphovascular invasion; tumors with any amount of micropapillary pattern showed higher propensity for lymphovascular invasion and lymph node metastasis compared with infiltrating duct carcinoma NOS. (74-78,81) Therefore, when an invasive micropapillary pattern is seen as a focal/partial component of a tumor, it is important to note the presence of this micropapillary element in the diagnosis. An estimate of the percentage of the micropapillary component would also be desirable. As increasing numbers of cases are described, a better understanding of this lesion may evolve if it was noted that the proportion of IMPC within an infiltrating duct carcinoma NOS has impact on outcome. A few studies have reported that a relatively higher percentage of IMPCs are positive for estrogen receptor (61%-91%), progesterone receptor (50%-70%), and Her2/neu (54%-78%) compared with infiltrating duct carcinoma NOS; however, other studies have not found a statistically significant difference in the expression of these proteins. (74,80,84) A higher frequency of p53 protein overexpression (38.9%-75%) has been noted among IMPC compared with infiltrating duct carcinoma NOS. (81,84-86) Thor et al (87) demonstrated chromosomal loss of the short arm of chromosome 8 in all of the 16 IMPCs studied. According to follow-up results of most series, a poor outcome (higher rate of recurrence, metastasis, and death from disease) is expected for patients with IMPC (75-77,81,84); however, the prognosis of IMPC does not differ from that of invasive ductal carcinoma NOS of similar stage, and therefore, the micropapillary pattern may not have any independent prognostic significance. (75,80) The more aggressive behavior appears to be related to the higher frequency of lymphovascular invasion and lymph node metastases.
The assessment of papillary lesions continues to be one of the most challenging areas in breast pathology. In this review, we have provided guidelines to distinguish and accurately diagnose the various papillary lesions based on H&E morphology with the adjunctive use of immunohistochemistry when needed. The incorporation of the concept of DIN into the terminology of papillary lesions not only provides an alternative way to categorize these lesions but also, and more important, avoids the use of the term carcinoma, preventing overtreatment as well as diminishing the psychological and social impact of a diagnosis of cancer on the patient.
The limitations of cytology in the diagnosis of papillary lesions have also been addressed. The management of papillary lesions found on core biopsy remains an issue of much debate, however. It would be prudent, in our opinion, to completely excise any papillary lesion where the initial core biopsy has not removed the lesion in its entirety. Some small papillary lesions are excised completely with the 8-gauge and 9-gauge needles, obviating reexcision. Epithelial displacement by needling procedures is not infrequently encountered because of the increasing popularity of these procedures, and the pathologist should be aware of this possibility. We are particularly concerned about the possibility that areas interpreted as invasion in association with the solid, encapsulated papillary carcinomas may, in fact, reflect dislodged tumor cells; because there are no ME cells around cells dislodged from a papillary DIN (DCIS) into the surrounding stroma, it is impossible to exclude true invasion. A rather long follow-up is necessary to confirm the true nature of such areas.
Variants of intraductal papillary carcinoma (DIN 1-3, papillary type), such as solid papillary carcinoma and encapsulated papillary carcinoma, have recently been implicated as possible low-grade invasive carcinomas based on the absence of ME cells around the circumscribed nodules; however, the fact that the majority of such lesions behave indolently should always be kept in mind to avoid the overtreatment of such patients.
Optimally, in our opinion, localized papillary lesions should be excised completely with a small rim of uninvolved breast tissue without any prior needle instrumentation if and when the papillary nature can be determined by imaging.
(1.) Fapotti M, Gugliotta P, Ghiringhello B, Bussolati G. Association of breast carcinoma and multiple intraductal papillomas: an histological and immunohistochemical investigation. Histopathology. 1984;8(6):963-975.
(2.) Ohuchi N, Abe R, Takahashi T, Tezuka F. Origin and extension of intraductal papillomas of the breast: a three-dimensional reconstruction study. Breast Cancer Res Treat. 1984;4(2):117-128.
(3.) Hart D. Intracystic papillomatous tumors of the breast, benign and malignant: analysis of one hundred and twenty-four cases. Arch Surg. 1 927;14(4):793-835.
(4.) Choi YD, Gong GY, Kim MJ, etal. Clinical and cytologic features of papillary neoplasms of the breast. Acta Cytol. 2006;50(1):35-40.
(5.) Gomez-Aracil V, Mayayo E, Azua J, Arraiza A. Papillary neoplasms of the breast: clues in fine needle aspiration cytology. Cytopathology. 2002;13(1):22-30.
(6.) Michael CW, Buschmann B. Can true papillary neoplasms of breast and their mimickers be accurately classified by cytology? Cancer. 2002;96(2):92-100.
(7.) Masood S, Loya A, Khalbuss W. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions? Diagn Cytopathol. 2003;28(6):329-334.
(8.) Simsir A, Waisman J, Thorner K, Cangiarella J. Mammary lesions diagnosed as "papillary" by aspiration biopsy: 70 cases with follow-up. Cancer. 2003;99(3): 156-165.
(9.) Saad RS, Kanbour-Shakir A, Syed A, Kanbour A. Sclerosing papillary lesion of the breast: a diagnostic pitfall for malignancy in fine needle aspiration biopsy. Diagn Cytopathol. 2006;34(2):114-118.
(10.) Field A, Mak A. A prospective study of the diagnostic accuracy of cytological criteria in the FNAB diagnosis of breast papillomas. Diagn Cytopathol. 2007;35(8):465-475.
(11.) Nayar R, De Frias DV, Bourtsos EP, Sutton V, Bedrossian C. Cytologic differential diagnosis of papillary pattern in breast aspirates: correlation with histology. Ann Diagn Pathol. 2001;5(1):34-42.
(12.) Rosen EL, Bentley RC, Baker JA, Soo MS. Imaging-guided core needle biopsy of papillary lesions of the breast. AJR Am J Roentgenol. 2002;179(5):1185-1192.
(13.) Renshaw AA, Derhagopian RP, Tizol-Blanco DM, Gould EW. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Am J Clin Pathol. 2004;122(2):217-221.
(14.) Sydnor MK, Wilson JD, Hijaz TA, Massey HD, Shaw de Paredes ES. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology. 2007;242(1):58-62.
(15.) Agoff SN, Lawton TJ. Papillary lesions of the breast with and without atypical ductal hyperplasia: can we accurately predict benign behavior from core needle biopsy? Am J Clin Pathol. 2004;122(3):440-443.
(16.) Ivan D, Selinko V, Sahin AA, Sneige N, Middleton LP. Accuracy of core needle biopsy diagnosis in assessing papillary breast lesions: histologic predictors of malignancy. Mod Pathol. 2004;17(2):165-171.
(17.) Rizzo M, Lund MJ, Oprea G, Schniederjan M, Wood WC, Mosunjac M. Surgical follow-up and clinical presentation of 142 breast papillary lesions di agnosed by ultrasound-guided core-needle biopsy [published online ahead of print January 18, 2008]. Ann Surg Oncol. 2008;15(4):1040-1047.
(18.) Ashkenazi I, Ferrer K, Sekosan M, et al. Papillary lesions of the breast discovered on percutaneous large core and vacuum-assisted biopsies: reliability of clinical and pathological parameters in identifying benign lesions. Am J Surg. 2007;194(2):183-188.
(19.) Valdes EK, Tartter PI, Genelus-Dominique E, Guilbaud DA, Rosenbaum Smith S, Estabrook A. Significance of papillary lesions at percutaneous breast biopsy. Ann Surg Oncol. 2006;13(4):480-482.
(20.) Murad TM, Contesso G, Mouriesse H. Papillary tumors of large lactiferous ducts. Cancer. 1981;48(1):122-133.
(21.) Woods ER, Helvie MA, Ikeda DM, Mandell SH, Chapel KL, Adler DD. Solitary breast papilloma: comparison of mammographic, galactographic, and pathologic findings. AJR Am J Roentgenol. 1992;159(3):487-491.
(22.) Carter D. Intraductal papillary tumors of the breast: a study of 78 cases. Cancer. 1977;39(4):1689-1692.
(23.) Lam WW, Chu WC, Tang AP, Tse G, Ma TK. Role of radiologic features in the management of papillary lesions of the breast. AJR Am J Roentgenol. 2006; 186(5):1322-1327.
(24.) Cardenosa G, Eklund GW. Benign papillary neoplasms of the breast: mammographic findings. Radiology. 1991;181(3):751-755.
(25.) Han BK, Choe YH, Ko YH, Yang JH, Nam SJ. Benign papillary lesions of the breast: sonographic-pathologic correlation. J Ultrasound Med. 1999;18(3): 217-223.
(26.) Orel SG, Dougherty CS, Reynolds C, Czerniecki BJ, Siegelman ES, Schnall MD. MR imaging in patients with nipple discharge: initial experience. Radiology. 2000;216(1):248-254.
(27.) Murad TM, Swaid S, Pritchett P. Malignant and benign papillary lesions of the breast. Hum Pathol. 1977;8(4):379-390.
(28.) MacGrogan G, Tavassoli FA. Central atypical papillomas of the breast: a clinicopathological study of 119 cases. Virchows Arch. 2003;443(5):609-617.
(29.) Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. Hum Pathol. 1994;25(8):802-809.
(30.) Page DL, Salhany KE, Jensen RA, Dupont WD. Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. Cancer. 1996;78(2): 258-266.
(31.) Lewis JT, Hartmann LC, Vierkant RA, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol. 2006;30(6):665-672.
(32.) Collins LC, Schnitt SJ. Papillary lesions of the breast: selected diagnostic and management issues. Histopathology. 2008;52(1):20-29.
(33.) Gown AM, Vogel AM. Anti-intermediate filament monoclonal antibodies: tissue-specific tools in tumor diagnosis. Surv Synth Pathol Res. 1984;3(5):369-385.
(34.) Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins, II: distribution of filament proteins in normal human tissues. Am J Pathol. 1984;114(2):309-321.
(35.) Gown AM, Vogel AM. Monoclonal antibodies to human intermediate filament proteins, III: analysis of tumors. Am J Clin Pathol. 1985;84(4):413-424.
(36.) Lacroix-Triki M, Mery E, Voigt JJ, Istier L, Rochaix P. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast: a comparative study with 34[beta]E12 antibody. Virchows Arch. 2003;442(6):548-554.
(37.) Jarasch ED, Nagle RB, Kaufmann M, Maurer C, Bocker WJ. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol. 1988;19(3):276-289.
(38.) Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology. 2000;37(3):232-240.
(39.) Moinfar F, Man YG, Lininger RA, Bodian C, Tavassoli FA. Use of keratin 35[beta]E12 as an adjunct in the diagnosis of mammary intraepithelial neoplasiaductal type--benign and malignant intraductal proliferations. Am J Surg Pathol. 1999;23(9):1048-1058.
(40.) Raju U, Crissman JD, Zarbo RJ, Gottlieb C. Epitheliosis of the breast: an immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast. Am J Surg Pathol. 1990;14(10):939-947.
(41.) Rabban JT, Koerner FC, Lerwill MF. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol. 2006;37(7):787-793.
(42.) Shah VI, Flowers CI, Douglas-Jones AG, Dallimore NS, Rashid M. Immunohistochemistry increases the accuracy of diagnosis of benign papillary lesions in breast core needle biopsy specimens. Histopathology. 2006;48(6):683-691.
(43.) Ichihara S, Fujimoto T, Hashimoto K, Moritani S, Hasegawa M, Yokoi T. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. Pathol Int. 2007;57(3):126-132.
(44.) Adair FE. Sanguineous discharge from the nipple and its significance in relation to cancer of the breast: a study based on 108 cases. Ann Surg. 1930; 91(2):197-209.
(45.) Estes AC, Phillips C. Papilloma of lacteal duct. Surg Gynecol Obstet. 1949; 89(3):345-348.
(46.) Lewison EF, Lyons JG Jr. Relationship between benign breast disease and cancer. AMA Arch Surg. 1953;66(1):94-114.
(47.) Haagensen CD. Diseases of the Breast. 3rd ed. Philadelphia, PA: Saunders; 1986:xiii.
(48.) Haagensen CD, StoutAP, Phillips JS. The papillary neoplasms of the breast, I: benign intraductal papilloma. Ann Surg. 1951;133(1):18-36.
(49.) Ciatto S, Andreoli C, Cirillo A, et al. The risk of breast cancer subsequent to histologic diagnosis of benign intraductal papilloma follow-up study of 339 cases. Tumori. 1991;77(1):41-43.
(50.) Dupont WD, Page DL. Risk factors for breast cancer in women with pro liferative breast disease. N Engl JMed. 1985;312(3):146-151.
(51.) Pellettiere EV II. The clinical and pathologic aspects of papillomatous disease of the breast: a follow-up study of 97 patients treated by local excision. Am J Clin Pathol. 1971;55(6):740-748.
(52.) Ali-Fehmi R, Carolin K, Wallis T, Visscher DW. Clinicopathologic analysis of breast lesions associated with multiple papillomas. Hum Pathol. 2003;34(3): 234-239.
(53.) Ohuchi N, Abe R, Kasai M. Possible cancerous change of intraductal papillomas of the breast: a 3-D reconstruction study of25 cases. Cancer. 1984;54(4): 605-611.
(54.) Raju U, Vertes D. Breast papillomas with atypical ductal hyperplasia: a clinicopathologic study. Hum Pathol. 1996;27(11):1231-1238.
(55.) Tan PH, Aw MY, Yip G, et al. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol. 2005;29(5):625-632.
(56.) Carter D, Orr SL, Merino MJ. Intracystic papillary carcinoma of the breast: after mastectomy, radiotherapy or excisional biopsy alone. Cancer. 1983;52(1): 14-19.
(57.) Gatchell FG, Dockerty MB, Clagett OT. Intracystic carcinoma of the breast. Surg Gynecol Obstet. 1958;106(3):347-352.
(58.) Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol. 2005;123(1):36-44.
(59.) Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, Schnitt SJ. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol. 2006;30(8):1002-1007.
(60.) Nicolas MM, Wu Y, Middleton LP, Gilcrease MZ. Loss of myoepithelium is variable in solid papillary carcinoma of the breast. Histopathology. 2007;51(5): 657-665.
(61.) Nassar H, Qureshi H, Volkanadsay N, Visscher D. Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol. 2006;30(4):501-507.
(62.) Mulligan AM, O'Malley FP. Metastatic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases. Int J Surg Pathol. 2007;15(2):143-147.
(63.) Solorzano CC, Middleton LP, Hunt KK, et al. Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg. 2002; 184(4):364-368.
(64.) Maluf HM, Koerner FC. Solid papillary carcinoma of the breast: a form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol. 1995;19(11):1237-1244.
(65.) Otsuki Y, Yamada M, Shimizu S, et al. Solid-papillary carcinoma of the breast: clinicopathological study of 20 cases. Pathol Int. 2007;57(7):421-429.
(66.) Fisher ER, Palekar AS, Redmond C, Barton B, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4), VI: invasive papillary cancer. Am J Clin Pathol. 1980;73(3):313-322.
(67.) Dixon JM, Page DL, Anderson TJ, et al. Long-term survivors after breast cancer. Br J Surg. 1985;72(6):445-448.
(68.) McDivitt RW, Holleb AI, Foote FW Jr. Prior breast disease in patients treated for papillary carcinoma. Arch Pathol. 1968;85(2):117-124.
(69.) Youngson BJ, Cranor M, Rosen PP. Epithelial displacement in surgical breast specimens following needling procedures. Am J Surg Pathol. 1994;18(9): 896-903.
(70.) Youngson BJ, Liberman L, Rosen PP. Displacement of carcinomatous epithelium in surgical breast specimens following stereotaxic core biopsy. Am J Clin Pathol. 1995;103(5):598-602.
(71.) Nagi C, Bleiweiss I, Jaffer S. Epithelial displacement in breast lesions: a papillary phenomenon. Arch Pathol Lab Med. 2005;129(11):1465-1469.
(72.) Siriaunkgul S, Tavassoli FA. Invasive micropapillary carcinoma of the breast. Mod Pathol. 1993;6(6):660-662.
(73.) Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003. World Health Organization Classification of Tumours; vol 4.
(74.) Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol. 2001;32(6):583-589.
(75.) Nassar H, Wallis T, Andea A, Dey J, Adsay V, Visscher D. Clinicopathologic analysis of invasive micropapillary differentiation in breast carcinoma. Mod Pathol. 2001;14(9):836-841.
(76.) Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am J Clin Pathol. 2004; 121(6):857-866.
(77.) Luna-More S, Casquero S, Perez-Mellado A, Rius F, Weill B, Gornemann I. Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast: review of 68 cases with follow-up of 54. Pathol Res Pract. 2000;196(1):35-39.
(78.) Ling C, Yu F, Lang RG, etal. Breast carcinoma with micropapillary features: clinicopathologic study and long-term follow-up of 100 cases. Int J Surg Pathol. 2008;16(2):155-163.
(79.) Gunhan-Bilgen I, Zekioglu O, Ustun EE, Memis A, Erhan Y. Invasive micropapillary carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol. 2002;179(4): 927-931.
(80.) Paterakos M, Watkin WG, Edgerton SM, Moore DH II, Thor AD. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol. 1999; 30(12):1459-1463.
(81.) Middleton LP, Tressera F, Sobel ME, et al. Infiltrating micropapillary carcinoma of the breast. Mod Pathol. 1999;12(5):499-504.
(82.) Nassar H, Pansare V, Zhang H, et al. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. ModPathol. 2004;17(9):1045-1050.
(83.) Li YS, Kaneko M, Sakamoto DG, Takeshima Y, Inai K. The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer. 2006;13(1):58-63.
(84.) Zekioglu O, Erhan Y, Ciris M, Bayramoglu H, Ozdemir N. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma. Histopathology. 2004;44(1):18-23.
(85.) De la Cruz C, MoriyaT, Endoh M, etal. Invasive micropapillarycarcinoma of the breast: clinicopathological and immunohistochemical study. Pathol Int. 2004;54(2):90-96.
(86.) Kim MJ, Gong G, Joo HJ, Ahn SH, Ro JY. Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. Arch Pathol Lab Med. 2005;129(10):1277 1282.
(87.) Thor AD, Eng C, Devries S, et al. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol. 2002;33(6):628-631.
Accepted for publication October 15, 2008.
From the Department of Pathology, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan (Dr Ueng); and the Department of Pathology, Yale University School of Medicine, Yale New Haven Hospital, New Haven, Connecticut (Drs Ueng, Mezzetti, and Tavassoli).
The authors have no relevant financial interest in the products or companies described in this article.
Reprints: Shir-Hwa Ueng, MD, Department of Pathology, Linkou Chang Gung Memorial Hospital, No. 5 Fu-Hsin St, Gwei-Shan, Taoyuan, Taiwan 333 (e-mail: firstname.lastname@example.org).
Shir-Hwa Ueng, MD; Thomas Mezzetti, MD; Fattaneh A. Tavassoli, MD
Table 1. Morphologic Features of Papillary Lesions Intraductal Papilloma/ Atypical Papilloma/ Papillomatosis Papilloma With X% DIN 1 Epithelial cell Benign heterogeneous DIN 1 (grade 1 nuclear population epithelial cells with atypia) <90% of the variable degree of lesion (in actuality, low-risk DIN rarely >60%) (intraductal hyperplasia) Pattern of Variable degree of DIN 1: monomorphic distribution low-risk DIN epithelial cells with (intraductal stratified, papillary, hyperplasia) with cribriform, or solid haphazard arrangement, pattern <90% of the overlapping nuclei, lesion (in actuality, whirling, streaming, rarely >60%) and formation of slitlike secondary lumens ME cells within Layer of ME cells in Absent or reduced in the duct papillae DIN 1 areas ME cells at the Present Present periphery of the duct DIN 1-3, Papillary Type/Papillary Intraductal Carcinoma (Papillary DCIS Grades 1-3) Epithelial cell DIN 1-3 2=90% of the lesion; usually population low-grade DIN population but may be intermediate or high-grade occasionally. Pattern of DIN 1-3 with stratified, papillary, distribution cribriform, or solid pattern 2 90% of the lesion ME cells within Usually absent but may be present the duct sporadically or, rarely, the entire retained layer may be present ME cells at the Usually present; may be absenta periphery of the duct Abbreviations: DIN, ductal intraepithelial neoplasia; DCIS, ductal carcinoma in situ; ME, myoepithelial cells. (a) See the second paragraph of the section on noninvasive papillary carcinoma. Table 2. Immunohistochemical Features of Papillary Lesions Intraductal Papilloma/ Atypical Papilloma/ Papillomatosis Papilloma With DIN 1 HMWCK (CK5/6, Diffuse or mosaic DIN 1 cells negative 34[beta]E12) positivity in ([approximately equal epithelial cells to] 92%) ME cell markers Positive in papillae and Positive in non-DIN 1 (p63, calponin, around the duct areas and around the CD10) duct; negative or reduced in DIN 1 areas ER Few epithelial cells DIN 1 cells usually positive diffusely positive DIN 1-3 (DCIS Grade 1-3), Papillary Type/ Papillary Intraductal Carcinoma HMWCK (CK5/6, DIN 1-3 cells negative ([approximately equal to] 34[beta]E12) 92%) ME cell markers Usually negative within the duct; may show (p63, calponin, sporadic positivity within the duct or, rarely, CD10) positivity in the entire retained layer of ME cells; usually positive around the duct ER Usually diffusely positive Abbreviations: CK, cytokeratin; DCIS, ductal carcinoma in situ; DIN, ductal intraepithelial neoplasia; ER, estrogen receptor; HMWCK, high molecular weight cytokeratin; ME, myoepithelial.